



Appendix H

Clinical Practice Guideline Topic Scoring Rubric

Table 1. Draft of Reviewer Scoring Sheet. Final content to be further developed for construct validity and interrater reliability. Application will also be developed in order to solicit this content.

ALL DOMAINS SHOULD BE SCORED BASED ON INFORMATION PROVIDED WITHIN THE CPG INTENT FORM, NOT JUST PERSONAL KNOWLEDGE AND/OR EXPERTISE OF THE SUBMITTED TOPIC

| Domain | Items | Score (1 (worst) to 5 (best)) | Multiply by | Weighted score |
|--|--|----------------------------------|----------------|----------------|
| 1. Disease Burden on the Health System <i>Items 7, 8</i> | <p>Do the intent authors demonstrate that this CPG will address a problem with substantial disease burden on the health system?</p> <ul style="list-style-type: none"> - Potential impact of CPG <ul style="list-style-type: none"> o Number of children and families impacted o Which medical professional/societies whom care for children would implement clinical recommendation? o What is the impact on non-pediatric providers? o What is the impact on practice? - Disease/Condition incidence or prevalence - High risk impact of disease/condition for children - High frequency of risk factors associated with the disease/condition - High frequency of avoidable risk factors associated with the disease/condition - Health priorities in agreement with CPG's needs - High impact on national health system - What is impact on science of pediatric medicine? | | 1 | |
| 2. Economic Impact on the Health System <i>Items 7, 8</i> | <p>Do the intent authors demonstrate that this CPG will address a problem with substantial economic impact on the health system?</p> <ul style="list-style-type: none"> -Economic effects on health system (cost of an individual patient is high during diagnosis or therapeutic process) -Disease/Condition associated with iatrogenic interventions that are significantly high in cost -High impact on national health system | | 1 | |



| | | | | |
|--|--|--|---|--|
| <p>3. Effectiveness <i>Items 1 to 8</i></p> | <p>Do the intent authors demonstrate that this CPG will be effective in its implementation based on current methods shown in methodologically adequate studies?</p> <ul style="list-style-type: none"> - Certainty about effectiveness of assessed interventions and technologies | | 2 | |
| <p>4. Evidence <i>Items 1 to 8</i></p> | <p>Do the intent authors demonstrate that this CPG will be based on strong evidence?</p> <ul style="list-style-type: none"> - Availability of effective methods shown by methodologically adequate studies | | 2 | |
| <p>5. Clinical Practice Variation <i>Items 8, 13</i></p> | <p>Do the intent authors demonstrate substantial and unwarranted variation in practice that could be improved by the CPG?</p> <ul style="list-style-type: none"> - Current evidence is insufficient or variable for disease control in the population - Lack of high-quality CPGs - Availability of high volume of evidence regarding the CPG topic - Evidence of inappropriate use of available technologies used in the treatment of condition (iatrogenic) - Conditions/diseases where effective treatments could reduce mortality or morbidity - Evidence of disagreements between current treatment and literature recommendation - Is there current controversy about topic importance? - | | 2 | |
| <p>6. Patient Safety <i>Items 7, 8</i></p> | <p>Do the intent authors demonstrate that this CPG will improve Patient Safety?</p> <ul style="list-style-type: none"> - Does the production of guideline on this topic improve patient safety, or effective in reducing harm? - Disease/condition associated with high incidence of adverse events or treatment sequela - High possibility of adverse events | | 2 | |
| <p>7. Patient Priorities <i>Item 8</i></p> | <p>Do the intent authors demonstrate that this CPG is of interest to patients and their families?</p> <ul style="list-style-type: none"> - High patient demand or interest - Concerns about patients' quality of life - Feasibility of patient empowerment - High acceptability of the topic between the general public and professionals affected by the use of the CPG | | 2 | |
| <p>8. Novel Methodology <i>Item 8</i></p> | <p>Do the intent authors demonstrate that this CPG will address new methods and technology?</p> <ul style="list-style-type: none"> - High importance of new methods and technology assessment - Fast diffusion of non-assessed technologies, availability of resources and sufficient time for technologies implementation | | 1 | |
| <p>9. Other social effects/Equity <i>Item 8</i></p> | <p>Do the intent authors demonstrate that this CPG will address social and health inequities?</p> <ul style="list-style-type: none"> - Will reduce inequities when implemented - Closes gap in health care disparities for children and families | | 1 | |



| | | | | |
|---|---|--|---|--|
| | <ul style="list-style-type: none"> - Absenteeism from work or school, inability to work, inequities in access to health services - Will the service be available to anyone who requires it? - Will this CPG have a positive or negative impact on minorities' access to health services? - Will the CPG increase health service access to those affected by the condition? | | | |
| 10. Health Promotion and Disease Prevention <i>Item 8</i> | <p>Do the intent authors demonstrate that this CPG will address health promotion and disease prevention?</p> <ul style="list-style-type: none"> - Feasibility of prevention between patients with risk factors - Are there specific activities of health promotion, disease prevention, early diagnosis or treatment? Have all of them shown a reduction in disease burden? | | 1 | |
| 11. Work Effort | <p>Do the intent authors demonstrate that the CPG is readily feasible to develop and implement without substantial barriers (e.g., complex problems, broad scope, financial, etc.)?</p> <ul style="list-style-type: none"> - Feasibility on recommendations development which will improve health outcomes and cost - Is the proposal politically feasible? - Does it belong to priority health areas according to government policies? - Can the CPG be implemented? For example, will not require an excessive amount of resources and will not present important barriers to implement changes - Will require education to training professionals - Does the proposed topic include a diverse and inclusive stakeholder group? - Complexity of systematic review - Information needs for members and their patients | | 1 | |
| TOTAL OF THE WEIGHTED SCORES ABOVE | | | | |
| Comments to the Board in Relation to the Submitted Intent and/or Domain Scoring Clarification: | | | | |

* Clinical Practice Guidelines up for revision will likely be scored higher priority because of decreased complexity and resources and increased alignment with AAP strategic plans.

Adapted from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846928/>

Updated November 2019